These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 8126248)

  • 101. Iron as the key modulator of hepcidin expression in erythroid antibody-mediated hypoplasia.
    Fernandes JC; Garrido P; Ribeiro S; Rocha-Pereira P; Bronze-da-Rocha E; Belo L; Costa E; Reis F; Santos-Silva A
    Biomed Res Int; 2014; 2014():421304. PubMed ID: 25580431
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure.
    Braun A; Ding R; Seidel C; Fies T; Kurtz A; Schärer K
    Pediatr Nephrol; 1993 Feb; 7(1):61-4. PubMed ID: 8439481
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Analysis of the factors in the cases resistant to recombinant human erythropoietin treatment.
    Suzuki M
    Contrib Nephrol; 1990; 82():65-71. PubMed ID: 2093529
    [No Abstract]   [Full Text] [Related]  

  • 104. The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply.
    Loo M; Beguin Y
    Blood; 1999 May; 93(10):3286-93. PubMed ID: 10233880
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Human recombinant erythropoietin reduces sensorimotor dysfunction and cognitive impairment in rat models of chronic kidney disease.
    Reza-Zaldívar EE; Sandoval-Avila S; Gutiérrez-Mercado YK; Vázquez-Méndez E; Canales-Aguirre AA; Esquivel-Solís H; Gómez-Pinedo U; Márquez-Aguirre AL
    Neurologia (Engl Ed); 2020 Apr; 35(3):147-154. PubMed ID: 29132915
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Application of recombinant human erythropoietin in patients with polycystic kidney disease and chronic renal failure.
    Dimitrakov D; Kunchev E
    Folia Med (Plovdiv); 1992; 34(1):41-4. PubMed ID: 1339766
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Anemia in acute renal failure: role for erythropoiesis-stimulating proteins?
    Liangos O; Pereira BJ; Jaber BL
    Artif Organs; 2003 Sep; 27(9):786-91. PubMed ID: 12940900
    [TBL] [Abstract][Full Text] [Related]  

  • 108. A review of the first year of Medicare coverage of erythropoietin.
    Griffiths RI; Powe NR; Greer J; de Lissovoy G; Anderson GF; Whelton PK; Watson AJ; Eggers PW
    Health Care Financ Rev; 1994; 15(3):83-102. PubMed ID: 10137799
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Stimulating erythropoiesis in inflammatory bowel disease associated anemia.
    Tsiolakidou G; Koutroubakis IE
    World J Gastroenterol; 2007 Sep; 13(36):4798-806. PubMed ID: 17828809
    [TBL] [Abstract][Full Text] [Related]  

  • 110. The safety of epoetin-alpha: results of clinical trials in the United States.
    Eschbach JW; Egrie JC; Downing MR; Browne JK; Adamson JW
    Contrib Nephrol; 1991; 88():72-80. PubMed ID: 2040198
    [No Abstract]   [Full Text] [Related]  

  • 111. Effects of the recombinant human erythropoietin (rHuEPO) administration on hematologic parameters, red cell creatine and 2,3-diphosphoglycerate contents, in patients affected by end-stage renal disease.
    Ricci G; Masotti M; De Paoli Vitali E; Vedovato M; Bedani PL; Gilli P
    Biomed Pharmacother; 1991; 45(8):349-52. PubMed ID: 1773023
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Iron therapy and cardiovascular disease.
    Sullivan JL
    Kidney Int Suppl; 1999 Mar; 69():S135-7. PubMed ID: 10084298
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Hematologic aspects of renal insufficiency.
    Schiller GJ; Berkman SA
    Blood Rev; 1989 Sep; 3(3):141-6. PubMed ID: 2676032
    [TBL] [Abstract][Full Text] [Related]  

  • 114. The effects of recombinant human erythropoietin on growth and nutritional status.
    Jabs K
    Pediatr Nephrol; 1996 Jun; 10(3):324-7. PubMed ID: 8792397
    [TBL] [Abstract][Full Text] [Related]  

  • 115. An indistinct balance: the safety and efficacy of parenteral iron therapy.
    Besarab A; Frinak S; Yee J
    J Am Soc Nephrol; 1999 Sep; 10(9):2029-43. PubMed ID: 10477157
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Effectiveness of recombinant human erythropoietin, vitamin D3 and iron therapy on long-term survival of patients with end-stage renal disease receiving haemodialysis: analysis of 702 patients after 10-year follow-up.
    Chang HC; Chen CL; Chiu TL; Chen SI; Yen AM; Chen TH
    Public Health Nutr; 2009 Dec; 12(12):2410-5. PubMed ID: 19344540
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Erythropoietin should be part of congestive heart failure management.
    Silverberg DS; Wexler D; Blum M; Schwartz D; Wollman Y; Iaina A
    Kidney Int Suppl; 2003 Nov; (87):S40-7. PubMed ID: 14531772
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Benefits and costs of recombinant human erythropoietin for end-stage renal failure: a review. Benefits and costs of erythropoietin.
    McNamee P; van Doorslaer E; Segaar R
    Int J Technol Assess Health Care; 1993; 9(4):490-504. PubMed ID: 8288425
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Management of renal anaemia: comparison of practice in the Czech Republic and Northern England.
    Lindley E; Pancírová J; Kraciková J; Lopot F; Green D; Harrington M; De Vos JY; Elseviers M;
    EDTNA ERCA J; 2004; 30(2):75-83. PubMed ID: 15368885
    [TBL] [Abstract][Full Text] [Related]  

  • 120. The pathological consequences of anaemia.
    Silverberg DS; Iaina A; Wexler D; Blum M
    Clin Lab Haematol; 2001 Feb; 23(1):1-6. PubMed ID: 11422223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.